Profhilo and JUVÉDERM SKINVIVE are often placed under the same “skin booster” heading, which makes them look like two prices for the same promise. That is the fastest way to make both services harder to sell. If the consultation script for each is simply “deep hydration and glow,” the client can only compare brand, price and popularity.
The products become easier to position when the clinic stops asking which syringe is better and asks a more useful question: which skin-quality service are we trying to build? Profhilo brings a hybrid-HA technology story and a planned opening course. SKINVIVE brings a crosslinked microdroplet gel, lidocaine and product-specific smoothness data. Those differences shape booking, expectation setting, stock and rebooking—not just the comparison table.
Quick answer
Choose the service model before the product
Profhilo fits a course-based bio-remodelling service built around IBSA’s BDDE-free NAHYCO hybrid complexes of high- and low-molecular-weight HA and its published two-session opening cycle. SKINVIVE fits a skin-smoothness service built around 12 mg/mL BDDE-crosslinked HA with 0.3% lidocaine, a treatment-and-review pathway, and clinical evidence tied to cheek smoothness and hydration.
A clinic can stock one or both. Carrying both makes commercial sense only when the team can explain two distinct outcomes and two distinct care pathways. Two services called “hydration” will eventually compete for the same appointment.
This guide compares product design, published evidence, menu roles and buying logic. It does not provide injection depths, doses or an individual treatment recommendation, and it does not claim that either product is clinically superior.
At a glance
The products share HA, but not the same clinic job
| Decision field | Profhilo | JUVÉDERM SKINVIVE | What it means for a clinic |
|---|---|---|---|
| Product platform | NAHYCO hybrid cooperative complexes of high- and low-molecular-weight HA; produced without BDDE chemical crosslinking | 12 mg/mL HA crosslinked with BDDE; 0.3% lidocaine | They need different training and consultation language, even though both sit in the skin-quality category. |
| Cytollia pack | One 2 mL prefilled syringe with two needles | Two 1 mL prefilled syringes | Stock counting and preparation differ. Pack format does not, by itself, define dose or number of services. |
| Published product role | Tissue remodelling and improvement of skin laxity; IBSA’s reviewed page names face and neck | Skin smoothness and hydration; U.S. product-specific evidence began with the cheeks and expanded to neck-line use in 2026 | Profhilo supports a remodelling-course conversation; SKINVIVE supports a defined smoothness outcome. |
| Opening pathway | IBSA publishes an initial cycle of two sessions 30 days apart, followed by maintenance as required | Initial treatment with a review/touch-up decision; 73% of participants in the original U.S. pivotal study received a touch-up at one month | Profhilo is course-led by design. SKINVIVE should not be promised as universally “one and done.” |
| Evidence signature | Hybrid-HA technology plus studies of hydration, roughness and laxity in defined populations | Randomized product-specific smoothness data, measured hydration and results through six months with optimal treatment | The evidence stories are different; there is no direct head-to-head winner. |
| Strongest menu name | Bio-remodelling course | Skin-smoothness service | The menu should sell two jobs, not two brands under one generic heading. |
Cytollia service architecture
Do not sell two versions of “deep hydration”
Most client-facing comparisons reduce Profhilo to firmness and SKINVIVE to glow. That shorthand is memorable, but it does not tell the clinic how to create services that stay distinct after the launch campaign ends.
A stronger menu starts with the journey. Profhilo asks the client to enter an opening course and understand that the value is built across scheduled visits. SKINVIVE can be framed around a defined smoothness goal, an initial treatment and a planned result review. That difference changes what the receptionist books, what the practitioner explains, what the client expects next and how the clinic measures repeat demand.
Laxity and crepey quality, or smoothness and hydration?
Hybrid-HA remodelling course, or crosslinked smoothness treatment?
A defined opening course, or treatment plus result review?
The winning SKU is the one that earns repeatable appointments.
Profhilo signature
Profhilo is easiest to sell as a course, not a syringe
Technology story
Hybrid HA without BDDE
IBSA describes Profhilo as stable hybrid cooperative complexes created by thermally combining high- and low-molecular-weight HA without chemical crosslinking agents. The Cytollia box contains 64 mg of HA in one 2 mL syringe.
This is a product-specific explanation a clinic can own. It is more defensible than generic phrases such as “pure hydration” or “premium skin booster,” which could be attached to dozens of products.
Menu story
A visible commitment to a planned pathway
IBSA’s published opening cycle consists of two treatment sessions 30 days apart. The clinic can therefore package Profhilo as a guided bio-remodelling course with a scheduled second visit and a later maintenance conversation.
The sales advantage is not that two visits are automatically better. It is that the client understands the pathway before buying and the clinic can build a reliable rebooking process around it.
Profhilo is especially coherent for clinics already receiving consultations framed around loss of firmness, skin laxity or crepey skin quality. It is less coherent when the team promises instant contour, treats the product as a filler substitute, or sells a single appointment while quietly relying on the client to discover the rest of the course later.
SKINVIVE signature
SKINVIVE sells a measurable skin-smoothness outcome
Product story
Crosslinked HA with lidocaine
The U.S. Directions for Use describe SKINVIVE as 12 mg/mL HA crosslinked with BDDE and formulated with 0.3% lidocaine. Cytollia’s current listing is a two-syringe box containing 1 mL per syringe.
The built-in lidocaine and the JUVÉDERM brand give the team concrete product features to explain, but neither should be turned into a universal claim about comfort or patient preference.
Evidence story
Defined smoothness and hydration endpoints
The original U.S. approval was built around improving cheek skin smoothness, with an effect lasting at least six months in the reviewed study. In June 2026, a U.S. label supplement added intradermal and/or subdermal use to reduce neck lines and improve neck appearance in adults over 21.
That precision is commercially useful: SKINVIVE can be presented as a product with specific skin-quality outcomes, while the exact local indication must follow the market and supplied SKU.
One detail deserves more attention than it usually receives. In the original pivotal study, 73% of participants received a touch-up at about one month. A clinic may still create a concise and convenient SKINVIVE service, but “one session for everyone” is not the strongest promise. A better structure is treatment, planned review and touch-up if the professional assessment supports it.
Clinic Fit Map
Match the consultation language to a service lane
Commercial inventory guide
The lower box price is not automatically the lower service cost
Profhilo and SKINVIVE currently occupy different price positions in Cytollia’s catalogue, but publishing the numbers here would make the article stale as soon as pricing changes. More importantly, a box-to-box comparison hides the care pathway.
A clinic with strong course conversion may find Profhilo commercially clean even when the opening commitment is larger. A clinic built around event-led skin-smoothness appointments may find SKINVIVE easier to position. The better purchase is the one whose complete pathway fits the business—not the one with the most attractive isolated syringe price.
Stocking snapshot
Three sensible ways to stock the category
Model 01
Profhilo-first clinic
Best aligned with a practice that already sells planned skin-quality courses.
- Strong laxity and crepey-skin consultation demand
- Reliable second-visit rebooking
- Staff comfortable explaining gradual change
- No need for a second generic hydration SKU
Model 02
SKINVIVE-first clinic
Best aligned with a practice that wants a sharply defined smoothness service.
- Cheek smoothness and hydration are common client words
- JUVÉDERM recognition supports consultation entry
- A result-review workflow is already in place
- The clinic can sell evidence, not “glass skin” hype
Model 03
Two-lane menu
Carry both only when the team can preserve separate roles.
- Profhilo: Bio-remodelling Course
- SKINVIVE: Skin Smoothness Service
- Different landing pages and consultation scripts
- Separate reorder and conversion tracking
The two-lane model can increase choice without creating confusion, but it needs discipline. If both services share the same headline, same before-and-after language and same “hydration” promise, the second SKU adds inventory before it adds demand.
Consultation talking points
Explain the difference without turning it into a contest
“These are not two strengths of the same treatment. Profhilo is organised as a bio-remodelling course; SKINVIVE is organised around a defined skin-smoothness result.”
“We will choose the service pathway that matches the concern first, then discuss the product and current price.”
“If the goal is facial shape or volume, we should assess that separately rather than asking a skin-quality product to do a contouring job.”
This language protects both credibility and margin. It gives the client a reason for the recommendation that is more substantial than brand prestige, while avoiding an unsupported claim that one product is universally newer, stronger or better.
What the evidence can support
Both have evidence, but not a head-to-head verdict
Profhilo’s clinical literature includes product-specific studies of hybrid cooperative complexes. A 2025 open-label study in 30 Chinese women reported significant improvement over time in superficial hydration and transepidermal water loss, while several other measures did not show significant pairwise changes. The study contributes useful population-specific evidence, but it was small, non-comparative and included IBSA employees among the authors.
SKINVIVE’s VYC-12L evidence includes a randomized multicentre study and the FDA’s product review. The FDA summary reports improved cheek smoothness in a 209-person study with results lasting at least six months. Additional VYC-12L research measured changes in hydration and firmness, though not every study used the same treatment area or design.
There is no robust direct trial establishing Profhilo or SKINVIVE as the universal winner. Cytollia therefore uses the evidence to define each product’s credible service role, not to manufacture a superiority claim.
Professional boundary
Skin-quality positioning does not remove injectable risk
Both products are injectable medical products and require appropriately qualified professional assessment, genuine product verification and the current instructions for the supplied market. Contraindications, warnings, expected reactions and emergency readiness belong in the clinic’s clinical governance—not in an Instagram promise of “zero downtime.”
Frequently asked questions
Questions clinics ask about Profhilo and SKINVIVE
Is SKINVIVE the same as Profhilo?
No. Profhilo uses thermally stabilised hybrid cooperative complexes of high- and low-molecular-weight HA without BDDE. SKINVIVE is a 12 mg/mL BDDE-crosslinked HA gel containing 0.3% lidocaine. Their published service structures and evidence stories also differ.
Which is better for hydration?
Both have hydration-related evidence, but “better” cannot be answered from a direct head-to-head trial. Profhilo is easier to position around a course-based bio-remodelling and laxity story; SKINVIVE is easier to position around defined smoothness and hydration outcomes.
Does SKINVIVE really need only one session?
It should not be promised as one session for every client. In the original U.S. pivotal study, 73% of treated participants received a touch-up about one month after the initial treatment. A treatment-and-review pathway is more accurate.
How many sessions are in the Profhilo opening course?
IBSA’s reviewed product page publishes an initial cycle of two sessions 30 days apart, followed by maintenance sessions as required. The actual plan remains subject to professional assessment and the current local product information.
Does SKINVIVE contain lidocaine?
Yes. The U.S. Directions for Use list 0.3% lidocaine. The Profhilo product reviewed here does not list lidocaine in its published composition.
Which product lasts longer?
SKINVIVE has FDA-reviewed cheek-smoothness results lasting at least six months with optimal treatment. Profhilo publishes a different course and maintenance model. Because the products, outcomes and studies differ, a simple duration winner would be misleading.
Should a clinic stock both Profhilo and SKINVIVE?
Yes, if each answers a different repeatable consultation need. Profhilo can anchor a bio-remodelling course and SKINVIVE a skin-smoothness service. If both are sold with the same hydration script, one is likely to become duplicate stock.
Which one costs less?
The live Cytollia product pages show the current price gap and tier pricing. Clinics should compare the cost of the complete service pathway rather than freezing a box price inside an article.
Current Cytollia catalogue
Compare the exact Profhilo and SKINVIVE listings
Review the current product format, availability and live commercial information before ordering. Prices are maintained on the product pages rather than embedded in this guide.
Course-led bio-remodelling roleProfhilo 2 mLView product and live tier pricing →
Outcome-led skin-smoothness roleJUVÉDERM SKINVIVE 2 × 1 mLView product and live tier pricing →
Current catalogue information may change. No fixed product price is stored in this editorial page.
Sources and editorial notes
- IBSA Derma — PROFHILO product information
- IBSA Derma Nordic — PROFHILO published protocol
- Allergan Aesthetics — SKINVIVE official product information
- U.S. FDA — SKINVIVE 2023 approval overview
- U.S. FDA — SKINVIVE clinician Directions for Use
- U.S. FDA — 2026 SKINVIVE neck-indication supplement
- Profhilo in Asian patients — open-label study
- VYC-12L randomized multicentre skin-quality study
- VYC-12L hydration and skin-quality attributes study
Last verified: August 5, 2026. Product names, composition, pack format, published service structure and regulatory statements were checked against the linked manufacturer, FDA and academic sources. Market indications and supplied documentation can differ by country.
Commercial disclosure: Cytollia sells both products linked in this guide. The comparison is organised around documented product differences and clinic service design; it does not determine clinical superiority or replace an appropriately qualified professional assessment.